Novo Nordisk a/s today
Novo Nordisk A/S.
- 52 weeks
- 77.82 dollars
▼
148.15 dollars
- Profit
- 0.92 %
- P/E ratio.
- 23.69
- The target price
- 145.25 dollars
Novo Nordisk shares, weight loss shares and diabetes. NYSE: NVO It has declined over the past 52 weeks. The shares decreased by 34 % during that period as of February 13. The new year did not provide a break, as the shares decreased by more than 8 %. The stocks are now trading less than 1 % above their lowest level in 52 weeks.
This big decline raises the question: Has the stock shares become attractive? Some of the large bank analysts give this question to this question. I will analyze the main measures of the last financial report from the company expected, as well as other important developments to give my opinion.
Novo Nordisk reports strong Q4 revenues and profit growth
In the fourth quarter, revenues and net profits in Novo grew vigorously by 30 % and 29 %, respectively. The well -known Ozambian drug, used to treat type 2 diabetes, showed moderate growth of 12 % sales. However, this is much slower compared to 60 % growth Elie Lily New York: Li Competitive drugs, mounjaro, achieve. On the other hand, Wegovy sales were starkly hot, rising 107 %. This is the same medicine as OzemPIC, but it treats obesity.
A 329 % increase in non -American revenue helped achieve this massive total growth. This is one field where Novo definitely has an advantage over a night. The night of the competitor was not registered against Wigovi, known as Zepbound, that is, sales outside the United States. Compared to the total sales growth of 26 % in 2024, Novo expects 16 % growth to 24 % in 2025.
On the horizon: increased production and a dilemma in my mind
In general, Novo has two special initiatives in particular for 2025. First I managed to provide more active ingredients in OzemPIC and Wegovy, Semaglutide. semaglutide Still on Food and Drug Administration List (FDA). This has restricted the growth in sales, allowing vehicles like Hims & HERS Health NYSE: HIMS To sell the product in the meantime. The FDA (FDA) has taken the competing Lilly formula, Tirzepatide, outside the list in October 2024. Novo has invested billions of dollars to increase production. The company has made great steps to enhance the show. It plans to serve 30 % of patients in 2025 by expanding operations.
The second task is to clarify the details related to weight loss and the treatment of next diabetes, Kagrisima. The injection injection only showed the loss of retired weight of the imaginary drug by 20.4 % compared to 20.1 % of the Zepbound. The results of the NOVO shares were sent in December 2024 as they failed to show weight loss much higher than the Zepbound.
An abnormal part of the study was that patients can reduce their dose if they needed. It is strange that the patients who ended their treatment at a lower dose 3 % have a greater weight From those who ended with the upper dose. Many are considered intuitive, as higher doses often lead to weight loss. Novo begins with a new experience that will start in the first half of 2025. It looks forward to exploring the duration of treatment and changing doses over time that can affect effectiveness. Current results show that the doses designed for each patient may enhance the effectiveness of my meeting.
In the end, it seems to me that the potential market for Cagrisma is estimated. There is an important reason to believe that the drug works very well for some patients, a corner that the company can tend to. However, you will need more results to come out to confirm this.
Less analyst classifications and evaluation compared to Lily suggested the upper direction
Novo Nordisk A/S Marketrank ™
- In general, Marketrank ™
- 93 Celsius
- Analyst classification
- Moderate purchase
- The upward trend/negative side
- 86.4 % up
- The level of short attention
- correct
- Profit power
- weak
- Environmental result
- us
- Feelings of news
- 0.45
- Trading from the inside
- us
- Bruges. Profit growth
- 20.73 %
See full analysis
Marketbeat has not tracked any targeted updates for the price of analysts for Novo Nordisk since profits. It may be sometimes difficult to obtain these classifications because Novo is a Danish company. However, two updates adapted in the Danish currency targeting an average price of 988 Danish Kroner (DKK), is about $ 136.70. Compared to 566 DKK (about $ 78.34) as of February 13, this goal involves a huge altitude of about 75 %. Currency fluctuations and other factors will cause differences in numbers in return and escalation compared to the receipt of American deposits in Novo (ADR).
Although I see this upward amount as optimistic, Novo’s shares seem to be somewhat least. The price of the front (P/E) is about 45 % of Lilly’s 38X. In my opinion, they both provide reasonable ways to play in this space for various reasons. Lilly is higher growth, while the comparative evaluation of Novo and depression feelings are upside down.
Before you think about Novo Nordisk A/S, you will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whom the top analysts quietly whispered to their customers to buy now before hunting the broader market … Novo Nordisk A/S was not in the list.
While Novo Nordisk A/S currently has a “moderate purchase” classification among analysts, analysts from senior exporters believe that these five stocks are better.
Show the five stocks here
Opening the immortal value of gold with the exclusive gold prediction report 2025. Explore why gold remains the final investment to protect wealth against inflation, economic transformations and global doubts. Whether you are planning for future generations or seeking a reliable origin in troubled times, this report is your primary guide to make enlightened decisions.
